Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2022 | Antibody-drug conjugates for advanced bladder cancer

Jonathan Rosenberg, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the use of antibody-drug conjugates such as enfortumab vedotin and sacituzumab govetican for patients with advanced bladder cancer, and the need to research the optimal sequencing of these agents. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.